Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients
(2023)
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients
Year:
2023
Type of item:
Articolo in Rivista
Tipologia ANVUR:
Articolo su rivista
Language:
Inglese
Referee:
No
Name of journal:
Journal of the European Academy of Dermatology and Venereology
ISSN of journal:
0926-9959
Page numbers:
100-102
Keyword:
psoriasis risankizumab safety
Short description of contents:
safety of risankizumab in patients with psoriasis and hepatitis B and C
Product ID:
133872
Handle IRIS:
11562/1094248
Last Modified:
October 31, 2024
Bibliographic citation:
Ciolfi, Christian; Balestri, Riccardo; Bardazzi, Federico; Burlando, Martina; Chersi, Karin; Costanzo, Antonio; Dapavo, Paolo; Gisondi, Paolo; Malagoli, Piergiorgio; Pizzolato, Miriam; Rech, Giulia; Paolo Russo, Francesco; Battistella, Sara; Piaserico, Stefano,
Safety profile of risankizumab in the treatment of psoriasis patients with concomitant hepatitis B or C infection: A multicentric retrospective cohort study of 49 patients«Journal of the European Academy of Dermatology and Venereology»
, 2023
, pp. 100-102